Sanofi is creating an app to help with depression for patients with MS. The company is working with Happify Health on the tool and is conducting proof of concept studies with several thousand MS patients before deciding whether to initiate a 510(k) certification.
The app is Sanofi’s first proposed digital therapeutic, and the company specifically chose MS as an entry point into the space because of its extensive experience with the condition, Ameet Nathwani, M.D., Sanofi’s chief medical officer and chief digital officer, said.
This is not planned as a one-off, either:
“This is a first foray, but we’re certainly talking to other companies about digital therapy approaches in other diseases. So yes, we see how this could become more of a portfolio play where we would have a portfolio of digital therapeutics which are clinically meaningful and could be used as prescribed agents,” he said.
Other stories from the Fierce network:
- Twitter taps Healthline Media veteran to oversee fast-growing U.S. health vertical
- Google, Mayo Clinic team up on patient data and AI healthcare research
- Success of nearly half of European cancer drug trials ‘exaggerated’ due to bias: report
- GSK CEO Walmsley to join Microsoft board as tech giant wades deeper into healthcare